TROP2 (Trophoblast cell surface antigen 2) is a type I transmembrane glycoprotein encoded by the TACSTD2 gene, initially identified in trophoblast cells of the embryo. TROP2 is widely expressed in various epithelial tissues and abnormally overexpressed in multiple solid tumors, such as breast cancer, lung cancer, pancreatic cancer, and colorectal cancer. Due to its high expression in tumors and its role in promoting tumor invasion and metastasis, TROP2 is regarded as an important oncogene and a therapeutic target for cancer treatment.
Genomeditech provides resources related to TROP2, including expression cell lines, proteins, and antibodies, which can be used for in vitro evaluation of TROP2-targeted drugs.
